Business Context and Reporting Period
This Form 8-K is a current report filed by Virios Therapeutics, Inc. (not Dogwood Therapeutics, Inc.) on May 13, 2021. The registrant is incorporated in Delaware and trades on the Nasdaq Capital Market under the symbol VIRI. The report addresses corporate governance and executive compensation matters.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on executive compensation adjustments rather than financial performance.
Material Changes
The primary material change disclosed is an adjustment to executive compensation:
- Officer: Ralph Grosswald, Vice President of Operations.
- Action: Salary increase approved by the Compensation Committee on May 7, 2021.
- Details: Annual salary increased from $199,875 to $224,859.
- Effective Date: June 1, 2021.
- Rationale: Alignment with base salary levels for similar positions among peer companies.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary on future performance, risks, contingencies, or unusual items. The document is limited to the disclosure of the salary adjustment.
Investor Verification Checklist
- Verify the correct registrant name is Virios Therapeutics, Inc. (VIRI), not Dogwood Therapeutics.
- Confirm the effective date of the salary increase is June 1, 2021.
- Review the company's most recent 10-K or 10-Q for comprehensive financial data, as this 8-K contains no financial statements.
- Check subsequent filings for any further changes to executive compensation or corporate governance.